Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ALIMTA in solid tumor patients with stable third-space fluid
2005-005535-10Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of pemetrexed in non-small cell lung cancer (NSCLC), pleural mesothelioma and peritoneal mesothelioma, sponsored by Eli Lilly and Company. Primary endpoint: Safety of pemetrexed in patients with third-space fluid. Started Jan 2006; status: completed.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)pleural mesotheliomaperitoneal mesothelioma
Beyond the preview
Go deeper on 2005-005535-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005535-10.